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1. Introduction
Epigenome is a common name for heritable chemical modifications of DNA and histone
molecules, of which DNA methylation and histone acetylation and methylation represent the
most studied parts. Nucleosomes, the chromatin building units, are positioned in a way that
is strictly dependent on the epigenome changes. Based on the presence of a specific epigenetic
modification, the chromatin becomes less or more condensed. These changes in chromatin
structure are inevitably related to gene activity. For example, DNA hypermethylation joined
with histone hypoacetylation is frequently related to a condensed form of chromatin, marking
the region of DNA that should not be active during a specific time window. This implies that
genes in that specific region may become active once the aforementioned marks are removed.
Indeed, epigenome represents a very powerful, extremely flexible “tool” for regulating gene
activity and the major reason for the well-known phenomena of “time specific” and “tissue
specific” gene expression.
In the field of cancer research, epigenome changes are considered to be among the first steps
in carcinogenesis, preceding the structural changes in the DNA molecule, known generally as
“gene mutations”. Specifically, the most prominent change in the earliest phases of cancer is
inactivation of tumor suppressor genes which are frequently silenced through DNA methyl‐
ation and histone deacetylation taking place in the regions corresponding to their promoters.
It is known that enzymes regulating these processes, DNA methyltransferases (DNMTs) and
histone deacetylases (HDACs) are aberrantly up-regulated not only in a developed cancer, but
also in the early phases of carcinogenesis (as recently shown for ductal in situ breast cancer [1]).
Accordingly, significant effort has been given to the discovery and development of specific
chemical compounds that may act as DNA demethylating agents and histone deacetylases
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inhibitors (HDACi). Some of these compounds are already utilized in the clinic, like DNMT
inhibitors 5-azacytidine and decitabine and HDAC inhibitor vorinostat, with specific thera‐
peutic indications [2]. In parallel with these research efforts, considerable data has been
published on the role of natural compounds. The importance of these compounds has been
intensely studied in the field of cancer prevention, especially in light of the influence of a
specific diet on cancer prevention (as shown for the Mediterranean diet which may have a
modest beneficial effect related to the incidence of colorectal carcinoma [3]). Many dietary
compounds have been revealed to significantly impact gene expression through modulating
the epigenome. Logically, if a specific type of diet is considered to be protective in relation to
cancer, there has to be a molecular mechanism at the level of the epigenome explaining its
protective effect.
These will be addressed in this book chapter, where we describe polyphenols’ molecular
mechanisms of action, through well-known compounds belonging to different chemical
subgroups and shown in Table 1.
2. Chromatin structure
The native state of DNA, a double helix, is formed when two antiparallel strands are held
together by hydrogen bonds (H-bonds) between complementary purine and pyrimidine bases.
Each human diploid cell contains approximately two meters of DNA. Obviously, in order to
be kept in the nucleus, which is, on average, nine micrometers in diameter, the DNA must be
10,000-20,000 folds compacted [4].
Histones are small proteins that act as chromatin "compacting units. The tight binding of DNA
and histones is considerably dependent on the charge: DNA is negatively charged molecule
due to presence of phosphate groups, and the strength of interaction between DNA and
histones strongly depends on posttranslational modifications of histones' tails which can
modify their charge. This is possible due to a specific structure of histone proteins. Histones'
globular domain represents central part that is highly structured. In addition to this part,
histone proteins have "tails" at both, NH2-and COOH-ends. These tails may be modified
through numerous types of posttranslational modifications of which methylation and
acetylation will be discussed in detail through this chapter. These covalent modifications, by
which cell regulates access to DNA, depend on enzymes often called "writers" and "erasers" [5].
2.1. Histone modifications and gene transcription
The part of the genome that contains genes that are dynamically transcribed must be shaped
in an open, flexible way. Part of the chromatin that follows this rule is called euchromatin.
Non-coding parts of genome, joined with those parts that contain inactive genes (e.g., in the
region of centromeres and telomeres) do not need to follow significant reshape. This con‐
densed, closed shape of chromatin is known as heterochromatin. So, how do histone modifi‐
cations influence keeping these two forms of chromatin present in the cell and, also important,
how do histone modifications influence "the switch" between the two forms? In other words,
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Polyphenol Plant sources
Quercetin
Apples, grapes, blackberries, cranberries, blueberries, onion, kale, capers,
watercress, dill, bitter dock, red wines, black tea
Kaempferol
Tea, kale, carrot, capers, leek, celery, apples
Luteolin
Sage, thyme, peppermint, carrot, broccoli, onion, chilli
Apigenin
Chinese cabbage, parsley, papper, garlic , barley, endive, olive oil, chamomile,
apples, onion
Genistein
Soy, soy food – miso, tempeh, tofu etc.
EGCG
Green tea
Curcumin
Turmeric (Curcuma longa), curry
Table 1. Structures and sources of selected polyphenols with known epigenome modifying activities.
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how is the need for expression of a specific gene during very short time period regulated by
histone posttranslational modifications?
There are two basic mechanisms: a) direct, influencing the overall structure of chromatin, b)
indirect, through the regulation of binding of effector molecules [6]. For example, trymethy‐
lation of lysine at the position 9 of histone 3 (H3K9me3) can recruit the protein HP1 (hetero‐
chromatin protein 1). The interaction takes place in the area of heterochromatin and leads to
additional compacting that physically precludes access of transcriptional machinery [7]. There
is sufficient level of evidence on cis-interactions in chromosome-mediated gene expression.
For example, H3S10 phosphorylation enhances H3K4 methylation and H3K14 acetylation, and
inhibits H3K9 methylation, thus indirectly facilitating chromatin decondensation [8].
The first report on histone acetylation is 50 years old [9]. The earliest studies following this
discovery, revealed association of hyperacetylated histones with gene transcription [10]. In
general, keeping in mind that there is no rule that would not have an exception, hyperacety‐
lation of histone tails induces transcriptional activation, while hypoacetylation is associated
with repression of transcription. Lysine acetylation is very dynamic process, regulated by
antagonistic actions of two groups of enzymes: histone acetyltransferases (HATs) and HDACs.
The consequence of lysine acetylation, which occurs upon the transfer of an acetyl group to
the ε-amino-group of lysine side chain, is neutralization of lysine's positive charge and hence
weakening interactions between histone and DNA. Mainly as a result of cumulative charge
neutralizations at multiple lysines, the chromatin takes its "open", transcriptionally active
structure [11]. This process is fast and happens in only a few minutes, as measured by isotopic
pulse labeling [12]. In general, HDACs have the suppressing function, they are negative
regulators of gene activity. It must be told that these enzymes have also many non-histone
protein substrates that are included in regulation of important cellular processes, including
cell proliferation and cell death. These are but not limited to: transcription factors, hormone
receptors, cytoskeletal proteins, chaperons and various signaling mediators.
Histone methylation certainly is one of the best studied histone modifications, which takes
place on both lysine and arginine amino acid residues. These modifications are not only
residue-dependent (K4, K9, K27, K36, K79 in histone 3 (H3)) but also status-dependent (mono-,
di-and trimethylation). In most scenarios, H3K4me2/3, H3K36me1/3 and H3K79me1/2 and
H4K20m1 modifications are associated with activation of transcription, while H3K9me2/3,
H3K27me2/3 and H4K20me3 marks are usually associated with transcriptional repression [13].
H3K4me3 association with 5' regions of active genes strongly correlates with overall tran‐
scription rate, active RNA polymerase II occupancy and global histone acetylation (reviewed
in [14]). Such outcome is a consequence of binding of different proteins that specifically interact
with activators or repressors of transcription.
Histone methylation depends on activity of histone methylating (histone lysine methyltrans‐
ferases, KMTs) and demethylating (histone lysine demethylases, KDMs) enzymes. Both
groups of enzymes have a very important role in cancer initiation and development and their
mutations have been shown to exist in different types of malignant tumors. Methylation marks
on histones are highly specific, altering gene expression in a way that may be unique for
particular type of normal and/or cancer cell [13]. For example, histone demethylase KDM5A
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contains a highly specific H3K4me3 reader domain and is probably involved in modifying
nearby domains upon binding to H3K4m3. This enzyme was found to be present in regions
that are enriched in H3K4me3 and are transcriptionally active. This is particularly significant
in cells originating from bone marrow and peripheral blood where high expression of its target
genes was also found [13]. For that reason, the ratio of various histone demethylases and
histone methyltransferases, KDM/KMT, was suggested to be a sign of a specific "transcription
module", trying to predict expression of specific genes, members of specific module. This fact,
which should provide more specific way of acting compared to acetylation balancing enzymes,
makes enzymes involved in regulation of histone methylation status good candidates for
specific epigenetic interventions.
Histone lysine methylation depends on KMTs that are classified into two groups, based on the
sequence and structure of their catalytic domains: SET domain containing (suppressor of
variegation homologus (SUV), enhancer of zeste proteins (EZH), trithorax-group (TrxG)
proteins) and non-SET domain containing (DOT1 protein family) [15].
So far, histone demethylases KDMs are grouped in two families. KDM1 family includes only
two members, LSD1 (lysine-specific demethylase 1, KDM1A) and LSD2 (KDM1B). LSD1 was
the first discovered histone demethylase and its discovery revealed that histone lysine
methylation is reversible process [16]. LSD1 targets histone H3K4, and, when associated with
androgen or estrogen receptor, it can also target histone H3K9. In addition, LSD1 has been
shown to demethylate non-histone proteins, including tumor suppressor p53 and DNA
methyltransferase-1 (DNMT1). The second, Jumonji C (JmjC) domain containing protein
family, is numerous and includes seven subgroups with a total of 14 KDMs. There is no doubt
that KDMs and KTMs must work coordinately in order to keep a precise regulation of histone
methylation.
Both KDMs and KTMs are involved in cancer initiation and progression, although KDMs are
much less studied. There are firm data on histone lysine methyltransferases expression change
upon cell exposure to heavy metals. For example, peripheral blood mononuclear cells (PBMC)
were isolated from the whole blood of healthy volunteers and exposed to varying concentra‐
tion of nickel chloride (0.25, 0.5 and 1.0 mM) for 24 h and compared to untreated control
samples. The transcriptome analyses (Affymetrix Human Genome U133.20 Array) combined
with ChipSeq with anti-H3K4me3, have revealed that there are 1381 entities with 2-fold
difference in expression upon nickel exposure. This number was reduced to 382 and 246 with
more stringent cuts off - 3-fold and 5-fold, respectively. The global level of H3K4me3 was
increased. This study also showed that H3K4me3 does not occupy only the promoters of genes
that were transcriptionally active, but also extends into their coding regions, as previously
shown for nickel-exposed human lung adenocarcinoma cell line A549 [17]. When measured
in PBMC from subjects that had occupational exposure to nickel but did not have cancer, the
level of H3K4me3 was significantly increased when compared with PBMC from subjects
without exposure [17]. Since chronic exposure to nickel has been associated with lung and
nasal carcinoma, these results, obtained on human population, clearly show that harmful
exposure indeed reshapes chromatin in a direction that leads to carcinogenesis. So, if detected
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early, before disease onset, can these changes be reversible? Even more so, can we influence
the enzymes that reshape epigenome in a procarcinogenic direction?
2.2. Interplay between DNA methylation and histone acetylation
There are several chromatin-regulating factors that recognize methylated DNA or modified
histone proteins. One of them, the HP1 protein, has already been mentioned. The common
characteristic of these effector molecules is that they use a range of different recognition
domains such as methyl-CpG-binding domains (MBD), zinc fingers (ZnF), chromo-domain,
or plant homeodomain (PHD) in order to direct establishing specific epigenomic marks and
orchestrate biological events [18, 19]. However, the most of studies performed so far have been
conducted using isolated DNA or histone peptides and cannot recapitulate the situation found
in chromatin in vivo. Recently, an approach named SNAP (SILAC nucleosome affinity
purification) was used for the identification of proteins that are influenced by DNA CpG
methylation and histone H3 K4-, K9- or K27-methylation (or a combination thereof) in the
context of a nucleosome. The approach itself seems to be very valuable in defining the
chromatin “interactome” and showing that DNA methylation and histone modifications act
in a concerted manner by creating a "modification landscape" that must be interpreted by
proteins able to recognize large molecular assemblies [20].
This is not surprising due to the fact that there are currently 18 HDACs identified in humans,
subclassified in four classes: a) class I HDACs 1, 2, 3 and 8 localized mainly in nucleus where
they acetylate numerous proteins, of which p53 (cellular tumor antigen p53) and BRCA1
(breast cancer type 1 susceptibility protein) are probably the most frequently studied non-
histonic substrates; b) class II with class IIa of HDAC 4, 5, 7 and 9 isoforms located in nucleus
and cytoplasm and class IIb of HDACs 6 and 10 located only in the nucleus; c) class III of
sirutins SIRT1-7 whose activity depends on the presence of nicotinamide adenine dinucleotide
(NAD+/NADH) and d) class IV containing only one enzyme, HDAC11 [21].
Besides actions on histone molecules, the importance of modifying "the guardian of genome"
p53 represents utmost important cellular event. One of the consequences of recruitment of
HDAC1 to p53, through MDM2 (E3 ubiquitin-protein ligase), is p53 deacetylation and
degradation. For this very reason, there is no p53-related induction of p21WAF1 (p21, cyclin-
dependent kinase inhibitor 1) and MDM2 [22]. Luckily, p21 is not regulated only by p53, but
also through many other transcription factors including Sp1 (transcription factor Sp1) for
which six binding sites are present in the p53 promoter. Thus, this is only one example of
multiple regulations and how complex the system has to be in keeping the balance of signals
that will prevent cell from uncontrolled division, which is a hallmark of cancer.
HDACi are generally subdivided into several groups, based on their diverse chemical
structures-short chain fatty acids, hydroxamates, cyclic peptides, aliphatic acids, benzamides,
SIRT inhibitors, electrophilic ketones and miscellaneous compounds [23]. The member of the
hydroxamate group, suberoylanilide hydroxamic acid (SAHA, vorinostat) has been approved
by FDA in October of 2006 for treatment of a rare cutaneous T-lymphoma. The approval for
the cyclopeptide, romidepsin (Istodax®), came in November of 2009. Although well tolerated
and with manageable side effects, HDACis have not entirely fulfilled expectations that were
based on well-known molecular mechanism associated with their application in vitro: early
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studies have undoubtedly shown that these HDACis upregulate p21 in p53-independent
fashion leading to G2/M cell cycle arrest [24]. Only two years later it was shown that this
treatment additionally increases cyclin E and decreases cyclin D1 [25].
As expected, the problem lies in insufficient selectivity of HDACis: in addition to an increase
of p21 and other pro-apoptotic genes, the treatment with HDACis also induces transcription
of genes that are pro-carcinogenic, like multiple isoforms of protein kinase C (PKC) and
downstream regulated matrix metalloproteinases (MMPs). Among 30 cancer cell lines (12 liver,
10 lung, 5 gastric and 3 breast cancer cell lines) that were tested for cell migration (indicating
metastatic potential) after being treated with HDACis belonging to different groups (including
vorinostat), 43% (13/30) cell lines showed several hundred folds increase in migration potential
[26]. This effect was initiated at low, non-cytotoxic sub-μM to low μM dosage of HDACis. In
an in vivo experiment, tumor cell lines were injected into HDACi treated mice. In contrast to
untreated control animals, these mice have developed metastatic disease with statistically
proved significance (p < 0.026). However, when combined with curcumin or tamoxifen, this
treatment had very promising effect both, in vitro and in vivo. Western blot analyses performed
on tumor lysates obtained from mice treated with HDACi trichostatin A, combined with
curcumin or tamoxifen revealed significant downregulation of PKCs and some other proteins
included in tumor progression. Of importance, the high expression of p21 induced with
HDACis remained unchanged.
It is well-known that dietary and other environmental factors induce epigenetic alterations.
For example, smoking induces numerous harmful epigenetic alterations that can be first steps
in malignant transformation. Accordingly, cellular epigenome may be protected from harmful
events through a proper diet and healthy way of living.
With development of sophisticated methods applicable in all fields of molecular biology,
anticancer properties have become proved for many natural compounds [27]. Their mode of
action frequently influences cellular epigenome through chromatin remodeling [28]. For
example, polyphenols can modulate chromatin structure through influencing expression of
chromatin remodeling enzymes, HDACs and DNMTs [29]. Targeting these proteins in
addition to various kinases (e.g. mitogen-activated protein kinases (MAPKs), phosphatidyli‐
nositide-3-kinase (PI3K), protein kinase B isozymes (AKT), Aurora B, Polo-like kinase 1
(PLK1)), poly(ADP-ribose) polymerase (PARP) and other epigenome modifying enzymes
KDMs (LSD1, JMJD3) and HATs (p300/CBP (CREB binding protein) coactivators) [30] make
them extremely powerful modifiers of cellular processes included in all aspects of cellular
survival and cellular death. Besides, for all these multilevel ways of acting, affecting a large
number of biochemical signaling pathways, natural polyphenols are excellent examples of
polypharmacological compounds.
3. Intracellular stability and nuclear localization of polyphenols
In order to exert their effect on chromatin organization, polyphenols must be stable and able
to enter cellular nucleus. There are numerous studies in the field of cancer research reporting
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on various changes in experiment-related pre-selected set of interesting proteins included in
cellular proliferation, after adding a polyphenol to cellular medium. However, their intracel‐
lular accumulation, stability and transformation are poorly understood. This is not surprising,
as there are only limited number of studies dealing with polyphenol’s cellular uptake and
efflux, their subcellular localization and intracellular stability [31]. These parameters are
crucial for understanding their mechanism of action and biological effects.
The polyphenols are usually assumed to bind to cellular membrane and/or are in the cytoso‐
plasm affecting membrane receptors and modulating kinases activity [32,33]. Polyphenols
whose effects on chromatin are described in this review, may cross both cellular and nuclear
membranes and enter nucleus. For example, quercetin has been shown to be localized mainly
in the nucleus of HepG2 cells [34,35]. Flavon apigenin has been reported to localize mostly in
nuclear matrix and less in cytosol, nuclear membranes and microsomes of prostate cancer cell
lines DU145, LNCaP and PC-3 [36]. By using a confocal laser scanning fluorescence micro‐
scope, the autofluorescence of galangin and kaempferol appeared stronger in the nucleus than
cytoplasm of mouse hepatoma Hepa-1c1c7 cells [37]. Among flavonoids, only flavonols
containing the conjugated 3-OH group (Figure 1), show autofluorescence and can be detected
by this approach. The highest percentage of curcumin in breast cancer cell line MCF-7 cells has
been found in membrane and decreases in the following order: membrane > cytoplasm >
nucleus > mitochondria [38]. The fluorescent conjugates of EGCG were localized onto the
membrane as well as in the cytoplasm and nucleus of mouse fibroblasts L-929 [39], but are
found on the membrane, in the cytoplasm and specifically in mitochondria of the human
umbilical vein endothelial cells (HUVECs) [40]. The largest fraction of soy isoflavone genistein
has been localized in cytoplasm, but it has also been registered in nuclei and mitochondria of
pooled female rat liver [41]. The associated concentrations of genistein were in the nmol/g
range, far below the concentrations required for most of its in vitro effects [41]. Concentrations
of parent polyphenols within cells in vitro are usually in low μM to sub-μM range [42].
Namely, significant portion of a polyphenol, such as in the cases of EGCG [43] and apigenin
[44], may be intracellularly transformed, depending on cell type and cell culture conditions,
particularly pH of the medium [43, 45]. At the cellular level, metabolic transformations of
polyphenols through phases I and II enzymes, have been well-documented, including
hydroxylation by CYP450 isoforms CYP1A2, CYP3A4 [44] and CYP1B1 [46] and methylation
of hydroxyl groups by catechol-O-methyl transferase (COMT) [31]. These reactions may be
necessary for generation of active metabolites, as is the case with conversion of apigenin into
its main metabolite, luteolin [47]. Furthermore, since polyphenols more or less readily
participate in redox processes, the contribution of their oxidized quinone/quinone methide
forms to their mechanisms of action may not be excluded [48], particularly when relatively
high concentrations of flavonoids (high μM to mM) have been applied to cells [31].
Metabolic conjugation alters the physicochemical properties of flavonoids and it is widely
assumed that this can affect their biological activity. Hence, for understanding the cellular
effects of parent polyphenol compounds, the influence of their uptake, intracellular metabo‐
lism, oxidation and localization should be taken into account or a priori excluded [49]. This is
enormously important when put in the context of cellular epigenome which is specific for each
Epigenetics and Epigenomics180
type of cell. It may not be surprising then that specific effects of metabolites are consistent with
findings that polyphenols’ actions are cell-type dependent.
As usual, observations presented in this review will be interpreted in terms of parent poly‐
phenol aglycons whose structures are shown within Table 1, but one should bear in mind that
they may be exerted by their metabolites and oxidized forms.
4. Dose-dependent effects of polyphenols
The cellular effects of polyphenols recorded in vitro are concentration- and time-dependent
[49,50]. Application of quercetin and EGCG as well as other polyphenols like resveratrol,
induces hormetic dose–response cellular phenomenon characterized by a low-dose stimula‐
tion and high-dose inhibition, often resulting in typical U-or J-shaped curves [50]. While
showing pro-oxidant properties joined with citotoxicity at high concentrations, low doses of
quercetin (1-40 μM) were shown to have antioxidant and chemopreventive properties [51].
Also, application of curcumin, even at a very low concentration (10 μM), and especially if
exposure was prolonged (up to 72 h), was shown to be cytotoxic for various cancer cells, but
not for fibroblasts WI-38 [52].
At the low μM doses, the polyphenols activate hormetic adaptive cellular stress response
signaling pathways that include various kinases and transcription factors [50]. As a result,
there is an activation of genes that encode stress resistance proteins such as antioxidant and
detoxifying enzymes, protein chaperones, neurotrophic factors, and other cytoprotective
proteins. Specific example of such a pathway is the Nrf2/ARE (NF-E2-related factor 2 /
antioxidant response element) pathway [50]. At these concentrations, these compounds are
not cytotoxic, but cytostatic. They commonly block the cell cycle in various cancer cells in
S/G2 and mitotic phase, leading to cell death. They also target multiple kinases that are
implicated in pathogenesis of cancer.
5. Plant polyphenols in cellular growth arrest and death
So far, all studied polyphenols have been shown to induce both, apoptosis and autophagy of
cancer cells, without affecting normal cells [53,54,55]. Epicatechin and quercetin have been
shown to stimulate autophagy by simultaneous promotion of cytoplasmic protein deacetyla‐
tion although with different potencies and, possibly, through distinct molecular pathways [53].
Selected polyphenols can induce G0/G1 (growth arrest effect) and / or G2/S (anti-mitotic effect)
phase cell cycle arrest of various human cancer cell lines [56]. The induction of autophagy and
apoptosis is a very important mechanism for cancer prevention by dietary polyphenols. It
represents an effective anti-cancer strategy since it is based on an effort to block or suppress
the multistage process of carcinogenesis which relates to six fundamental hallmarks of cancer:
self-sufficient proliferation, insensitivity to anti-proliferative signals, evasion of apoptosis,
unlimited replicative potential, maintenance of vascularization, and, finally, tissue invasion
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and metastasis [57,58]. In addition, chemoprevention based on dietary polyphenols is not
expected to be accompanied by side effects since they are selectively toxic for the cancer cells.
Mechanistically, polyphenols have been shown to induce growth arrest and increase apoptosis
in cancer cells in various ways. Antiproliferative effects of dietary polyphenols are generally
associated with their capacity to regulate response to oxidative stress and/or DNA damage,
suppress angiogenesis, and inhibit various pro-proliferative signaling pathways. They affect
all aspects of carcinogenesis at its different stages through inhibition of various survival
transduction pathways related to NF-κB, PI3K, AKT and MAP kinases, as well as by stimu‐
lating expression of tumor suppressor genes (p53, BRCA1 and BRCA2) [57,58]. All polyphenols
studied so far, except apigenin, are able to modify redox cellular state as potent radical
scavengers [59]. They are also direct inhibitors of enzymes included in production of reactive
endogenous radicals. In addition to the effect on their enzymatic activity, dietary polyphenols
are also modulators of expression of proteins related to cellular antioxidant defenses and
detoxification, often through regulation of transcriptional activity of Nrf2.
These multiple effects of dietary polyhenols have been reviewed many times so far. Here, we
are focused on reviewing recent studies of some polyphenols’ influence on alteration of gene
expression through modulating epigenome by affecting DNA methylation and posttransla‐
tional modifications of histone proteins. Natural compounds seem to offer a huge source of
epigenetically active compounds of which flavonoids - flavonols quercetin and kaempferol,
flavones apigenin and luteolin, isoflavone genistein, catechin EGCG and curcuminoid
curcumin certainly take a very important place.
6. Quercetin
Quercetin is strong natural antioxidant flavonol ubiquitously present in dietary plant sources
(Table 1) [59]. Cellular sensitivity and specific response to quercetin depends on sensitivity to
hydrogen peroxide, H2O2. For example, quercetin induces formation of 8-oxo-7,8-dihydro-2'-
deoxyguanosine (8-oxodG), an indicator of oxidative DNA damage, in HL-60 cells, while in
their H2O2-resistant clone, HP 100 cells, this effect does not occur [60]. This, again, shows that
mode of action of specific nutraceuticals depends on cellular "molecular background".
In addition to its substantial redox activity, quercetin has multiple intracellular molecular
targets, affecting different signaling processes that are altered in cancer cells, with limited or
no toxicity against normal cells. Accordingly, quercetin inhibits carcinogenesis primarily
through inhibition of pro-proliferative signaling pathways. It has been found to be a pleiotropic
kinase inhibitor [61]. At 2 μM concentration, quercetin was shown to decrease the activity of
16 recombinant kinases by more than 80%, including ABL1, Aurora-A,-B,-C, CLK1, FLT3,
JAK3, MET, NEK4, NEK9, PAK3, PIM1, RET, FGF-R2, PDGF-Rα and –Rß [62]. Many of these
kinases are positive regulators of cell cycle. Thus, through simultaneous targeting of multiple
pathways related to these kinases, quercetin may act as antiproliferative agent [61].
Part of quercetin’s effects has been attributed to its ability to influence histone acetylation
(Figure 1). Quercetin was reported to block the binding of different transactivators including
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p300, CREB2, c-Jun, C/EBPβ and NF-κB to to the promoter of proinflammatory gene, COX2
(cyclooxygenase-2) [63]. As a consequence, there is a decrease in the level of the COX-2 protein.
Generally, COX-2 decrease is considered to be a very beneficial step to a successful cancer
chemoprevention [63,64]. While there is no doubt that quercetin affects numerous signaling
pathways, one of these was well-explained on mouse intestinal epithelial cell line MODE-K,
through its inhibitory effect on Akt phosphorylation, but without affecting cytoplasmic IKK
(inhibitor of nuclear factor kappa-B (IκB) kinase) activity. Thus, in this experimental model,
quercetin had no direct effect on NF-κB activation. Instead, it inhibited recruitment of the NF-
κB cofactor p300/CBP to the promoters of inflammatory genes IP-10 (10 kDa interferon gamma-
induced protein, C-X-C motif chemokine 10) and MIP-2 (WD repeat-containing protein 26),
through modulation of histone H3 acetylation and phosphorylation [65]. At 5 μM concentra‐
tion, quercetin was reported to increase acetylation of histones H3 and H4 induced by
trichostatin A in A549 (expressing wild-type p53) and H1299 (a p53 null mutant) lung cancer
cell lines, through p53 independent pathway [66].
Quercetin has also been found to effect activity of class III histone deacetylases SIRTs. Due to
the fact that biological effects of polyphenols depend on their own chemical stability and
metabolism, it is sometimes hard to predict whether in vitro test results may precisely predict
the situation in the living organism, in vivo. For example, it has been observed that quercetin
increases deacetylase activity of recombinant SIRT1, but at cellular level it inhibits SIRT1
activity [67]. This has been explained by metabolic transformation of quercetin. When
quercetin’s metabolite, quercetin-3-O-glucuronide, was taken instead of quercetin, an inhibi‐
tory function on recombinant SIRT-1 was shown. However, quercetin activates SIRT1 deace‐
tylase activity in hypoxia-exposed or hypoxic preconditioned HepG2 cells similarly to
resveratrol, resulting in hypoxic down-regulation of c-Myc and β-catenin [68].
Sirtuins affect the acetylation status of histones as well as other important cellular non-histone
proteins like HIF-1α, c-Myc and β-catenin [68]. SIRT1-mediated histone deacetylation (H1K26,
H3K9, H3K14, H4K16) is associated with the formation of heterochromatin. On the other hand,
SIRT1 interacts with numerous transcription factors and, through modifying their acetylation
Figure 1. Epigenetic factors modulated by quercetin. Ring and atom annotations of 2-phenyl-1,4-benzopyrone scaf‐
fold.
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status, modifies their function. For example, in the presence of stress stimuli, SIRT1 deacety‐
lates p53 and FOXO3 (forkhead box protein O3) leading to inhibition of apoptosis [69]. Another
mechanism for inhibition of stress-induced apoptosis is through deacetylation of repair factor
Ku70 (X-ray repair cross-complementing protein 6) and consequential sequestration of the
proapoptitic factor BAX (Bcl-2-associated X protein) away from mitochondria [70]. While
SIRT1 is capable of protecting cells from p53-induced apoptosis, its activity augments apop‐
tosis in response to TNF-α (tumor necrosis factor alpha) by deacetylating RelA/p65 at lysine
310 and thus supressing transcription of NF-κB regulated genes [71].
Quercetin has been found to affect other class III HDAC, SIRT6, in vitro. Using frontal affinity
chromatographic techniques, it has been found to inhibit deacetylase activity of immobilized
recombinant SIRT6 protein against H3K9 [72].
Quercetin effects have been mostly studied on blood cancers. It induces apoptosis and
autophagy of human leukemia HL-60 cells through orchestrating various signaling pathways
and chromatin remodeling [73]. It has been reported to induce significant histone hyperace‐
tylation at concentrations 75 and 100 μM in human leukemia cells, indicating the possible
involvement of histone hyperacetylation in its in vitro anticancer activity [73,74].
Quercetin has also been found to influence DNA as well as protein methylation levels.
Hypermethylation of the tumor suppressor gene p16INK4a (p16, cyclin-dependent kinase
inhibitor 2A) in human colon cancer cell line RKO was successfully reversed after 120 h of
treatment with quercetin [75]. This effect was concentration dependent.
Quercetin inhibiting activity against demethylase LSD1 was shown recently [76]. LSD1,
commonly upregulated in cancer, has critical role in controlling the transcription of genes
involved in cell growth and differentiation [77], and its inhibition may have significant
therapeutic value. LSD1 functions primarily in multiprotein complexes, which includes, for
example, HDAC1/2 and SIRT1.
Quercetin, as well as other catechol polyphenols, may indirectly inhibit DNMTs and thus DNA
methylation, through changing intracellular concentrations of S-adenosyl methionine (SAM)
and S-adenosyl-L-homocysteine (SAH) in a manner illustrated in Figure 2 [78].
7. Kaempferol
Kaempferol is a flavonol found in various vegetables (Table 1). In comparison with quercetin,
it has considerably lower antioxidant capacity due to missing catechol moiety [59]. It possesses
only 4’-OH group at ring B (Figure 1). However, like quercetin, kaempferol has a wide range
of pharmacological activities, including antioxidant, anti-inflammatory and anticancer activity
[79]. It suppresses growth of a number of human cancer cell lines in a concentration-dependent
manner, through inducing an arrest in G0/G1 or G2/M phases of cell cycle [80]. Depending on
the type of the cell, kaempherol can induce apoptosis [81,82] and autophagy [80]. For example,
it induces apoptosis of human breast cancer cells MCF-7, by initiation of intrinsic caspase
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cascade and down-regulation of the expression of nuclear kinase PLK1, an early trigger for
G2/M transition and mitotic progression [83].
In human liver and colon cancer cell lines (HepG2, Hep3B, HCT-116) kaempferol (5-100 μM)
was shown to induce a prominent reduction of cell viability and proliferation rate, partly
mediated through induction of hyperacetylation of histone H3 complex [81]. By performing
in silico molecular docking analysis and in vitro profiling on these cancer cell lines, kaempferol
has been recognized as a pan-inhibitor of human HDACs of classes I, II and IV [81].
Treatment of the chronic myelogenous leukemia cell line K562 and promyelocitic human
leukemia U937 with 50 μM kaempferol resulted in inhibition of PI3K and dephosphorylation
of Akt at Ser473 and Thr308 as well as in an increase of the expression of deacetylase SIRT3
and its mitochondrial localization [84]. Finally, apoptotic death of these cells upon kaempferol
exposure was a consequence of the induction of mitochondrial phase of the apoptotic program
with an aforementioned increase of SIRT3, joined with an increase of BAX, decrease of Bcl-2,
release of cytochrome c, and caspase-3 activation. Kampferol was also shown to be an inhibitor
of recombinant SIRT6 activity [72].
Figure 2. Indirect inhibitory effect of polyphenols with catechol (quercetin, luteolin) or galloyl (EGCG) moiety on
DNMTs activity. In the O-methylation process of these polyphenols catalysed by the enzyme COMT, DNMT co-factor
SAM is transformed into SAH which inhibits DNMTs and COMT.
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Similar to quercetin, kaempferol has shown inhibitory effect on histone demethylase LSD1
[76]. This enzyme has been reported to inversely regulate expressions of iodothyronine
deiodinases of type 2 (D2) and type 3 (D3), acting as a molecular switch that dynamically finely
tunes cellular needs for active thyroid hormone during myogenesis [85]. Kaempferol has been
known to interfere with many aspects of the thyroid hormones synthesis [86]. LSD1 relieves
the repressive marks (H3K9me2/3) on the DIO2 promoter and the activation marks
(H3K4me2/3) on the DIO3 promoter. This action is well-orchestrated and depends on LSD1
interaction with transcription factor FoxO3.When FoxO3 binding to DNA is abrogated, LSD1
cannot induce D2.
8. Luteolin
Luteolin is a flavone widely distributed in the plant kingdom (Table 1). In difference to
quercetin, it misses conjugated 3-OH group in C-ring (Figure 1) which considerably contributes
to high radical scavenging capacity of quercetin [87]. Accordingly, luteolin is less efficient
radical scavenger than quercetin [59]. However, the rest of structures of luteolin and quercetin
are similar and hence similar biological activities have been observed. Both flavonoids have
3’-, 4’-catechol moiety in B-ring, resorcinol-like A-ring and extended π-electron delocalisation
through whole skeleton. Luteolin inhibits growth of various cancer cell lines in a concentration-
dependent manner [88]. The most common effect induced with luteolin, as well as other
studied polyphenols with resorcinol-like structure of A-ring, is G2/M arrest of the cell cycle
[88]. However, underlying mechanisms of action vary among flavonoid family members,
primarily due to different number and positions of other hydroxyl groups at a common flavone
(2-phenyl-1,4-benzopyrone) backbone, leading e.g. to different antioxidant capacities and
intracellular metabolic transformations. The difference in antioxidative capacity of considered
flavonoids may be relevant for the observed differences in biological activities as well as
molecular mechanisms of action. For example, as quercetin, luteolin induces apoptosis in
HL-60 cells [60]. However, luteolin acts in non-oxidative way via forming a luteolin-topoiso‐
merase II-DNA ternary complex and thus mediates DNA cleavage.
In addition to modulation of cellular redox level and inhibition of topoisomerases I and II, the
underlying antiproliferative activities of luteolin relate to suppression of cell survival path‐
ways including those related to PI3K/Akt, NF-κB and X-linked inhibitor of apoptosis protein
(XIAP). It also stimulates apoptotic pathways, including those that depend on the induction
of the p53 [89, 90].
Luteolin also inhibits recombinant LSD1 in vitro [76]. Actually, due to the sequence homology
between LSD1 and monoamine oxidases (MAO) catalytic domains, some synthetic MAO
inhibitors such as trans-2-phenylcyclo-propylamine (TCP) and well-known natural MAO
inhibitors [91,92] including luteolin, quercetin and curcumin (but not EGCG and apigenin)
have been detected as potent inhibitors of LSD1 [76]. Since TCP treatment of embryonic kidney
cell line HEK293 increases SIRT1 at the protein level (without recordable effect on SIRT1
mRNA level), the potent natural LSD1 inhibitors may be also expected to elevate the level of
SIRT1 protein.
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As measured with colorimetric HDAC Activity Assay Kit, luteolin at 50 μM inhibited total
HDAC activity joined with increased acetylation of histones H3 and H4. No doubt, this finding
suggests that this dietary flavonoid plays an important role in regulation of gene expression
and, consequentially, has an inhibitory effect on growth of various tumor cells (LNM35, HT29,
HepG2, MCF7/6 and MDA-MB231-1833) [93].
The resorcinol-like A ring was also found to be a part of flavonoid pharmacophore accounting
for SIRT6 inhibition. Accordingly, luteolin inhibits deacetylase activity of recombinant SIRT 6
against H3K9 [72]. Furthermore, since luteolin is also the substrate of COMT [94], it may
indirectly inhibit DNMTs by elevating endogenous SAH concentration (Figure 2) [78].
Histone H3 phosphorylation (H3S10) is a result of Aurora kinase B activity. This specific
epigenetic mark is the hallmark of mitosis. Similar to quercetin [62], luteolin inhibits recombi‐
nant Aurora B enzymatic activity (equilibrium dissociation constant KD 5.85 μM) [95]. Its
inhibitory effect on endogenous Aurora B activity in different cancer cell lines was also
documented [95]. The consequence of this inhibition, which was shown to be dose-dependent,
is down-regulation of H3S10 phosphorylation after 24 h treatment. Inhibition of Aurora B
kinase activity was also observed for fisetin and 3-hydroxyflavone [95], indicating that this
effect may be related to common 2-phenyl-1,4-benzopyrone backbone (Figure 1).
In addition to inhibiting Aurora B kinase activity and hence reducing H3 phosphorylation
(Figure 3), luteolin has been found to decrease the acetylation status of histone H4 at the
promoter of the pro-proliferative kinase PLK-1 in PC-3 cells [88], leading to transcriptional
silencing of this oncogene [83].
Luteolin is a ligand for the nuclear type II [(3)H]estradiol binding site-a binding domain on
histone H4 [88]. Although, it has also been reported to stimulate c-Fos and p21 and inhibit the
cell cycle pathway genes, these changes are considered to be only supportive factors in
regulation of proliferation. The data obtained so far suggest that type II ligands, including
luteolin, inhibit cell growth and proliferation through epigenetic control of key genes involved
in cell cycle progression [88].
9. Apigenin
Apigenin is a flavone ubiquitously present in vegetables and fruits (Table 1). It induces cell
cycle arrest, p53-dependent apoptosis as well as autophagy of different cancer cells. Like other
polyphenols, apigenin is selectively toxic to cancer cells. However, it is much weaker radical
scavenger when compared to already described flavonoids [59]. Its mechanism of action
depends on cancer cell type, indicating possible existence of structural modifications caused
by cellular metabolism. For example, apigenin (50 μM) blocks cellular proliferation through
G2/M phase arrest of myeloid HL60 cells, leading to caspase-dependent apoptosis [96]. In
contrast, it (100 μM) blocks erythroid TF1 cells in G0/G1 phase leading to autophagy. In both
cell lines the JAK/STAT pathway was one of major apigenin targets.
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Treatment of monocytic leukemia cells THP-1 with apigenin (50 μM) induced DNA damage
mediated by kinases PKCδ and p38 [97]. The cell cycle progression at G1/S was delayed and
joined with the increased number of apoptotic cells. The PKCδ-dependent phosphorylation of
ataxia-telangiectasia mutated (ATM) kinase and histone γH2AX (a marker of double strand
DNA breaks) upon treatment with apigenin, resulted in transcriptional down-regulation of
genes involved in cell-cycle control and DNA repair. This indicates that THP-1 cells may be
unable to repair DNA damage induced by apigenin, hence triggering apoptosis.
Exposure of LNCaP (hormone-dependent / p53 wild type) and PC-3 (hormone-independent /
p53 mutant type) prostate cancer cells to apigenin (and also genistein, see next section) resulted
in same pattern of cell cycle arrest and apoptosis, associated with p21 up-regulation and PLK1
suppression [98].
Apigenin (20-40 μM) treatment of prostate cancer cells PC-3 and 22Rv1 resulted in the
inhibition of HDACs of class I, particularly HDAC1 and HDAC3, at the mRNA and protein
levels [99]. Apigenin-mediated HDAC inhibition resulted in reversal of aberrant epigenetic
events that promote carcinogenesis, that is, in global histone H3 and H4 acetylation, as well as
localized hyperacetylation of histone H3 on the p21 promoter. A corresponding increase in p21
and BAX mRNA and protein expressions resulted in cell cycle arrest and induction of apoptosis
in both cell lines. This effect was additionally demonstrated in vivo by studies of PC-3 xeno‐
grafts in apigenin-fed athymic nude mice.
Like already described flavonoids, arginin modulates recombinant SIRT6 deacetylase activity
although more weakly than quercetin [72].
10. Genistein
Genistein is an isoflavone abundant in soybeans. Genistein represents a prototype of a
phytoestrogen able to bind to nuclear hormone receptors ER-α and ER-β. It also down-
regulates androgen receptor in androgen-dependent prostate cancer cell lines such as LNCaP
[100]. It has been investigated as a chemopreventive agent against various cancers, particularly
hormone-responsive breast and prostate malignancies. According to numerous in vitro
experimental results accompanied with in vivo models, it displays pro-apoptotic, antimeta‐
static and antiangiogenic properties.
Genistein is only moderately strong radical scavenger [59]. However, this isoflavone exerts
antioxidant effects on cellular level at low μM concentrations, which correspond to physio‐
logically relevant concentrations in plasma. The plasma level of genistein in women consum‐
ing soy products was observed to be 0.74-6.0 μM [101]. Already at concentration of 0.5 μM,
genistein increases antioxidant status of cells via i) interaction with estrogen receptors, ii)
activation of ERK1/2 and iii) nuclear translocation of p50 subunit of NF-κB, resulting in an
overexpression of MnSOD (manganese-dependent superoxide dismutase) and consequential
lowering of intracellular peroxide levels [102].
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Genistein can arrest cell growth and induce apoptosis in various hematological cancer cell lines
[103] and cell lines of solid tumor origin (e.g. HCT-116 and SW-480 [104]). Its influence on
modulation of cell cycle most commonly relates to induction of G2/M cell cycle arrest, as shown
in breast, colon, malignant glioma and prostate cancer cell lines [104,105,106]. At a molecular
level, this effect is commonly dependent on tumor suppressors p53, p21 and/ or p16 [106].
While genistein’s anticancer effects appears similar in different cancer cell lines, the underlying
molecular mechanism of its action depends on a cell type. For example, genistein was shown
to have a strong inhibitory effect on cellular growth followed by apoptosis, on two different
prostate cancer cell lines, LNCaP-androgen-sensitive and DuPro – androgen resistant.
However, it induced G0/G1 and G2/M cell cycle arrest in LNCaP and DuPro cells, respectively
[107]. In addition, cellular effects of genistein on cancer cell cycle are very dependent upon
applied dose [103].
Genistein has been one of the first specific protein tyrosine kinase inhibitors which was
described almost 30 years ago [108,109]. As already stated, genistein antagonizes estrogen-and
androgen-mediated signaling pathways [106]. It has also been found to intervene in other
cellular signal transduction pathways inhibiting carcinogenesis through inhibition of NF-κB
and Akt signaling [57,109]. Significant part of genistein’s action, including growth inhibition
and cytotoxicity, relates to its inhibitory effect on topoisomerase II. This was very clearly shown
through resistance to genistein in a model of murine transgenic cells lacking topoisomerase II
beta [110,111].
Besides, genistein is also a potent modifier of epigenetic events including DNA methylation
and/or histone acetylation – directly, or through steroid receptor dependent process [101]. In
both aforementioned prostate cell lines, LNCaP and DuPro, genistein treatment (10-25 μM)
reshaped the chromatin structure [107]. The treatment increased acetylation level of histones
H3 and H4 at the transcription start sites of the two tumor suppressor genes, p21 and p16. It
also increased expression of transcriptional activators HATs, but did not change the global
methylation status of these cells.
Genistein’s  effect  on  breast  cancer  cells  is  selective  as  shown recently  [112].  In  a  dose-
dependent  manner  genistein  inhibits  both  precancerous  (normal  human  mammary
epithelial cells stably transfected with SV40  and human telomerase reverse transcriptase,
hTERT) and cancerous breast cells growth. Of importance, the apoptotic process was more
prominent  in  precancerous  than in  cancerous  breast  cells,  indicating  the  strong preven‐
tive potential. At the same time, there were only minor effects when applied to (commer‐
cially available)  normal  mammary epithelial  cells  [112].  In vivo,  orthotopic breast  cancer
mouse model was used. The animals were orally-fed with genistein enriched diet (modi‐
fied AIN-93G diet supplemented with 250 mg/kg genistein, corresponding to high-soy diet
in humans). In these animals, genistein has inhibited breast cancer growth; the tumors had
considerably  lower  wet  weight  and  significantly  less  PCNA  (proliferating  cell  nuclear
antigen) positive cells,  when compared with tumors that were developed in the animals
fed with diet that was not supplemented with genistein. At the mRNA level, there was a
strong increase in expression of tumor suppressor genes p16 and p21, and dramatic decrease
of oncogenes BMI1 (polycomb complex protein BMI-1) and c-MYC. These changes in mRNA
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expression clearly point out genistein’s effect on epigenome. Indeed, this was confirmed in
experiments that showed that genistein induces formation of euchromatine in the region
that covers promoters of p21 and p16, through changing the ratio of activating and repressive
histone modifications. Specifically, genistein treatment increased histone H3 acetylation and
formation of H3K4me3 and, at the same time, decreased formation of suppressive chroma‐
tin marks, H3K9me3 and H3K27me3 [112]. These changes were mild in breast cancer cells,
but  very  prominent  in  precancerous  breast  cell  line,  indicating,  one  more  time,  the
importance  of  genistein  in  the  process  of  cancer  prevention.  Based on  several  scientific
reports, especially in the field of breast cancer, it seems that genistein significantly influences
KTMs, while its effect on HDACs does not seem to be so prominent [112].
In breast cancer cell lines MCF-7 (ER-α positive) and MDA-MB 231 (ER-α negative) genistein
(18.5 μM) induces decrease in trimethylated marks at H3K27, H3K9 and H3K4, at six selected
genes: EZH2 (histone-lysine N-methyltransferase that adds methyl group to H3K27), BRCA1,
ER-α, ER-β, SRC3 (steroid receptor coactivator protein 3, that displays HAT activity) and p300
[113]. Genistein treatment also affected histone acetylation marks in close proximity of these
six selected genes recorded as an increase in H4K8ac and H3K4ac modifications.
In MDA-MB-231 cells, genistein (25 μM) restored ER-α expression by remodeling the chro‐
matin structure in the ER-α promoter [112, 114,115]. This is very beneficial effect, as it increases
tamoxifen-dependent anti-estrogen therapeutic sensitivity in vitro and in vivo. In addition, this
effect was synergistically enhanced when combined with HDACi trichostatin A.
There are also experimental data on genistein’s effect on colon cancer cells. When applied to
HT29 cell line, genistein has been reported to have inhibitory effects on HDAC activity with
IC50 value of 97 ± 18 μM [116]. Furthermore, incubation of HT29 cells with high concentration
of genistein (200 μM) resulted in a significant decrease of HDAC1 protein. Similar results were
obtained on human esophageal squamous cell carcinoma cells KYSE 510, in which 5 μM and
100 μM genistein inhibited 13.2% and 33% of HDAC activity, respectively [101].
Genistein was also observed to decrease expression of HDACs in other types of cells, as well.
In aforementioned human breast cancer cell lines, MCF-7 and MDA-MB-231, genistein
treatment (15 and 10 μM,) induced reduction (2 and ~ 4 fold, respectively) in expression of
HDAC1 protein [117]. Genistein (25 μM) has been reported to significantly downregulate
expression of class II HDAC6 protein in prostate cancer cells, LNCaP [100]. Since HDAC6 is a
Hsp90 deacetylase, such a change leads to an increase in the acetylated form of Hsp90 and
hence inhibition of its chaperone activity. The consequence of the lack of the chaperone
function is ubiquitin-mediated degradation of androgen receptor protein. However, in
difference to its structural isomer apigenin (Table 1), genistein does not modulate activity of
recombinant SIRT6 [72].
In addition to its impact on histone acetylation and methylation, genistein was also shown to
influence DNMTs in vitro, at the transcriptional level and also through inhibition of DNMT1
activity [117,118]. It reduces methylation specifically at promoters of tumor suppressor genes
thus affecting cancer cell survival [101]. In KYSE 510 cells treated with 2–20 μM genistein, the
inhibition of DNMT1 activity was associated with demethylation of the CpG islands specifi‐
cally in the promoters of p16, RAR-β (retinoic acid receptor beta) and MGMT (O6-methylgua‐
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nine methyltransferase) resulting in their consequential transcriptional reactivation [101,118].
Because genistein is a weak inhibitor of DNMTs, it does not induce global genomic hypome‐
thylation but selective hypomethylation at hypermethyated region of genomic DNA, corre‐
sponding to aforementioned tumor suppressor genes, p21 and p16 [117].
Genistein can restore the expression of genes silenced by DNA hypermethylation in breast
cancers not only by inhibiting enzymatic activity of DNMT1, but also through decrease of
DNMT1 protein level [117]. Increased expression of DNMT1, DNMT3a, and DNMT3b is
common in various cancer types, including breast cancer. Treatment of MCF-7 and MDA-
MB-231 cell lines with genistein (as well as with other polyphenolic DNMT1 inhibitors, EGCG
or curcumin), resulted in a significant decrease not only of HDAC1, but also of DNMT1 and
MeCP2 protein levels, joined with a significant decrease in the transcript levels of all three
DNMTs-DNMT1, DNMT3a, and DNMT3b [117]. The genistein effects on cell viability of these
breast cancer cells were dose-dependent with IC50 values of 15 and 10 μM for MCF-7 and MDA-
MB-231cells, respectively.
The inhibitory effects of genistein on DNMTs and HDACs may have an intrinsic synergistic
effect [101]. Genistein has been observed to have additive effects on the reactivation of
methylation-silenced genes in combination with other DNMT inhibitor decitabine or a HDAC
inhibitor trichostatin A [101].
11. EGCG
The (-)-epigallocatechin-3-O-gallate (EGCG) is the most abundant catechin in green tea,
accounting for 50-70% of green tea catechins [119]. Other green tea catechins are (−)-epigallo‐
catechin (EGC), (−)-epicatechin-3-gallate (ECG) and (−)-epicatechin (EC).
EGCG is a strong free radical scavenger [59]. Its antioxidant activity is additionally enhanced
by induction of expression of phase II detoxifying and antioxidant enzymes such as glutathione
S-transferases (GST), glutathione peroxidase (GPx), glutamate cysteine ligase (GCL), heme
oxygenase-1 (HO-1) and many other enzymes involved in the elimination or inactivation of
reactive oxygen species (ROS) and electrophiles implicated in multi-stage carcinogenesis.
EGCG acts through Nrf2/ARE dependant way via activated Akt and ERK1/2 signaling and /
or through modifying cysteine thiols of Keap1 (Kelch-like ECH-associated protein 1), a
repressor of Nrf2 [120]. EGCG can also inhibit carcinogenesis by modulating some other
transduction pathways including JAK/STAT, Wnt and Notch [57,121]. EGCG-induced
inhibition of EGFR (epidermal growth factor receptor) pathway is well-documented. It also
negatively influences topoisomerase II [122]. In majority cancer cell lines tested so far, this
catechin induces G0/G1 phase cell cycle arrest. Finally, EGCG induces apoptosis through both,
p53-dependent and p53-independent pathways. These activities, joined with an inhibitory
effect on NF-κB and MMPs, leads also to inhibition of angiogenesis, invansion and metastasis
formation [119,121]. In addition to all these processes, chemopreventive and anticancer effects
of EGCG are also based on modifications of epigenetic processes, selectively in the cancer cells.
In vitro studies show that EGCG enters cellular nuclei and binds to both DNA and RNA [122].
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As already stated, DNA methylation patterns and histone modifications significantly differ
between normal and tumor cells. Accordingly, selective targeting of epigenetic marks that
makes the difference between these two kinds of cells is a challenge in cancer therapy. In cancer
prevention, selective "preservance" of protective epigenetic marks represents an imperative
that deserves specific attention. In the field of therapy, reexpression of DNA methylation-
silenced tumor suppressor genes by inhibiting the DNMTs (DNMT1, DNMT3A, and
DNMT3B) has emerged as an effective strategy [123].
EGCG is a natural non-nucleoside inhibitor of DNMT1, undergoing clinical testing [124].
DNMT1 is overexpressed in the S-phase of cell cycle, particularly in highly proliferating cells,
which are the basic feature of cancer. This enzyme has a high preference for hemimethylated
DNA and is essential for maintaining the methylation pattern during each round of DNA
replication. Strong inhibitory effect of EGCG with IC50 at 0.47 μM on human DNMT1-mediated
DNA methylation was independent of the COMT-mediated methylation of EGCG (Figure 2)
[78]. EGCG inhibits activity of the DNMT1 molecule directly by binding to its catalytic site
through formation of H-bonds [78,125,126]. This binding is stabilized by Mg2+ions [78]. The
galloyl moiety was shown to most considerably contribute to high-affinity of EGCG for human
DNMT1. Thus, DNMT1 is also directly inhibited by other polyphenols with galloyl or also
pyrogallic acid (e.g. myricetin) moiety [78].
In breast cancer cell lines MCF-7 and MDB-MB-231 EGCG, like genistein and also curcumin,
downregulates transcription of not only DNMT1, but also de novo DNMTs, DNMT3a, and
DNMT3b. The effect extends to the proteins, lowering the level of DNMT1, HDAC1, and
MeCP2, known to interact with methylated DNA CpG regions [117]. Its effects on MCF-7 and
MDB-MB-231 cell viability were dose-dependent with IC50 of 10 and 15 μM, respectively.
Similarly to genistein, EGCG may, in physiologically attainable concentrations, reverse
aberrant gene hypermethylation [101,118,126]. In vitro demethylation of specific promoters has
been shown in various cancer cell types for many genes including p16, MGMT, hMLH1 (human
mutL homologue 1), GSTP1 (Glutathione S-transferase Pi) and/or RARβ [118,126]. Epigenetic
silencing of a phase II enzyme GSTP1 has been recognized as a molecular hallmark of human
prostate cancer. Exposure of human prostate wild-type p53 cancer cell lines, LNCaP and MDA
PCa 2b, to green tea polyphenols and EGCG alone (5-20 μM) for several days caused a
concentration-and time-dependent reactivation of this enzyme, through extensive demethy‐
lation in the proximal GSTP1 promoter and regions distal to the transcription factor binding
sites. This specific action of green tea polyphenols was correlated with the inhibition of both,
DNMT1 expression and activity [127]. Of importance, exposure of LNCaP cells to green tea
polyphenols did not result in global hypomethylation, but, instead, promoted maintenance of
genomic integrity. Additionally, the exposure of LNCaP cells to EGCG reduced transcriptional
activity of genes coding for HDACs 1-3 which also resulted with their decrease at the protein
levels. This molecular change was joined with the increased level of acetylated histones H3
(H3K9 and H3K18) and H4.
In the context of uniqueness of cellular epigenome, in human epidermoid carcinoma cells A431
the EGCG (5-20 μM) treatment did decrease global DNA methylation level. Expectedly, it was
joined with decrease of DNMT1 transcript, protein and enzymatic activity in a dose-dependent
manner, although far less than upon the treatment with clinically approved demethylating
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drug decitabine (5 μM) [128]. In this model, EGCG treatment resulted in re-expression of the
mRNA and proteins of silenced tumor suppressor genes p16 and p21. There was also an
increase in histones H3 (H3K9 and H3K14) and H4 (H4K5, H4K12, H4K16) acetylation and
decrease in level of methylated H3K9. These phenomena were ascribed to decreased level of
HDAC activity in A431 cells upon EGCG treatment [128].
In pancreatic metastatic adenocarcinoma cells AsPC-1, EGCG (10 μM) was also shown to
induce Raf kinase inhibitor protein (RKIP) via, in part, the inhibition of HDAC activity [129].
At the same time, this treatment repressed activation of ERK and upregulated E-cadherin
expression. Histone H3 expression was also increased, while Snail (zinc finger protein SNAI1)
expression, NF-κB nuclear translocation and MMP-2 and-9 activities were inhibited. Of great
importance, the treatment decreased metastatic potential of these cells.
Inhibition of HDAC activity and HDAC1 protein expression was recorded in a model of human
colon carcinoma, HT29 [116]. EGCG at concentration 100 μM, inhibited HDAC activity by
about 50%. Concomitantly, a significant decrease of the HDAC1 protein level was observed
depending on EGCG concentration (significant reduction at concentrations ≥ 50 μM).
EGCG mediated, dose-and time-dependent inhibition of class I HDACs (HDAC1, 2, 3 and
8)  joined with  the  increased acetylation  of  histone  H3 and p53,  were  shown in  experi‐
ments that were performed on prostate cancer cell lines LNCaP and PC-3 [130]. Acetyla‐
tion  of  p53  resulted  in  its  binding  to  the  promoters  of  p21  and  BAX  genes  leading  to
increased accumulation of cells in the G0/G1 cell cycle phase and induction of apoptosis.
Acetylation of p53 at Lys373 and Lys382 results in p53 accumulation due to block of its
MDM-2 mediated ubiquitination [130]. Finally, EGCG was suggested to contribute also to
proteasomal degradation of class I HDACs [130].
Similar to quercetin, EGCG and polyphenols with the galloyl moiety in general, stimulate the
activity of recombinant SIRT1 enzyme under stabilizing antioxidant conditions (achieved by
adding vitamin C or catalase) [67]. Without stabilization, recombinant SIRT1 became a target
for strong inhibition by these polyphenols [49], probably due to their auto-oxidation and
H2O2 formation [67]. These data point to the importance of testing in vitro stability of poly‐
phenol aglycons and tentative effects of actual products of their (bio)chemical transformations.
For example, quercetin did not show any effect on the deacetylation activity of SIRT1 in HT29
cells [67].
In addition to its influence on HDACs, EGCG has been identified as a specific inhibitor of
majority of HATs [131]. In HeLa cell nuclear extract, EGCG at 100 μM concentration inhibited
90% of HAT activity while no changes in total HDAC, SIRT1 and histone methyltransferase
activities were observed. The observed inhibitory action on NF-κB activation by EGCG has
been ascribed to its inhibition of RelA (p65) acetylation rather than the direct inhibition of p65
phosphorylation. The mechanism was explained using HEK293 cells in which EGCG (100 μM)
abrogated p300-induced p65 acetylation. Hypoacetylation of p65 increases the level of
cytosolic IκBα which prevents p65 translocation into the nucleus, thus interrupting the TNFα-
induced cascade of events.
EGCG (50 μM) inhibitory effect on HATs may be beneficial in hormone dependent prostate
cancer due to suppression of agonist-dependent androgen receptor (AR) activation by
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downregulation of its acetylation. Consequentially, AR remains "locked" in the cytoplasm and
cannot activate AR-related gene transcription [132]. Like p65, androgen receptor is also
acetylated by p300/CBP and PCAF (HAT KAT2B)/TIP60 (HAT KAT5), supporting the
hypothesis that HAT coactivators compete with HDAC corepressors for binding to promoter
regions and/or protein substrates and determine the level of transcription.
12. Curcumin
Curcumin (1,7-bis(4-hydroxy-3-methoxy-phenyl)-1,6-heptadiene-3,5-dione) is a natural
yellow-coloured curcumoid whose medicinal properties have long been recognized in
traditional Indian Ayurvedic medicine [133]. This chemical is an important part of curry spice
mix. It was brought to Western world in the 14th century.
Like other well-known polyphenols, curcumin has diverse pharmacological properties
including chemopreventive activity [134]. Its proven antioxidative, anti-inflammatory,
antiproliferative and antiangiogenic effects brought it in the focus for use in cancer prevention.
Recently its impact on cell signal transduction pathways by regulation expression and/or
activity of various proteins including NF-κB, Akt, MAPK, p53, Nrf2, Notch-1, JAK/STAT, β-
catenin, and AMPK (5'-AMP-activated protein kinase) has been reviewed [135]. Curcumin
induces growth arrest at G1 or G2/M phase of cell cycle leading to apoptosis of cancer cells of
various types. Indeed, if one molecule has an influence on all these processes, then it has to be
that it triggers basic biochemical processes in the cell.
Pharmacokinetic analyses have shown that its concentration in human plasma is far below
concentrations measured in experimental cell culture systems [136]. The most likely explana‐
tion for its observed biological activity may be related to the possibility that curcumin exerts
its biological activity through remodeling the epigenome network. If this kind of action indeed
takes the place, one would expect that lower concentrations are required for various biological
actions.
Indeed, curcumin is a strong modulator of epigenome [137]. It reduces histone acetylation
mainly via inhibition of HAT activity [138,139]. Its first epigenome-modifying activity was
shown in 2004 through its specific inhibition of acetyltransferase activity of p300/CBP in
cervical cancer cells, HeLa [138]. The consequence of this event was acetylation inhibition of
histones H3 and H4 with IC50 ~ 25 μM. This effect was specific since the HAT activity of PCAF,
histone deacetylase HDAC1 and histone methyltransferases remains unchanged. Curcumin
binding to the active site of p300 also abolished p300-mediated acetylation of p53. This may
be of great importance because p300/CBP directly interacts with and acetylates p53, enhances
its transcriptional activation ability and, consequently, DNA repair. However, due to the fact
that p53 can be target of other HATs that are not inhibited by curcumin, its acetylation status
upon curcumin treatment remained in the physiological range.
Curcumin’s HAT p300/CBP inhibitory activity is based on its Michael reaction acceptor
functionality where its α, β unsaturated carbonyl groups in the linker (Table 1) act as reaction
sites [140]. Its binding to p300/CBP induces conformational changes which result in decreased
binding afinities of histones and acetyl CoA for p300 [138]. Curcumin has also been reported
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to promote proteasome-dependent degradation of p300 and CBP without affecting the HATs
PCAF or GCN5 [140].
HAT inhibition may be a base for a variety of pharmacological effects of curcumin. HATs, have
been implicated in cancer cell growth and survival, and as such, HATs represent therapeuti‐
cally relevant molecular targets for anticancer drug development. HAT inhibitors also seem
promising for the treatment of Alzheimer’s disease and diabetes [141]. As a co-activator, p300/
CBP also enhances NF-κB transcriptional activity by acetylating NF-κB/p65 as well as sur‐
rounding histones. Direct inhibition and downregulation of p300/CBP therefore contribute to
the inhibition of NF-κB by curcumin. Curcumin’s influence on NF-κB activity is extremely
important for its chemopreventive potency [142]. Additionally, its anti-infectious activities
against HIV-1 [138] and Plasmodium falciparum [143] can also arise from inhibition of HAT
activity.
In addition, on HeLa nuclear extracts curcumin showed the potent activity as an inhibitor of
HDAC [144]. At a very high concentration of 500 μM, curcumin was found to reduce ~ 50%
HDAC activity and its IC50 was 115 μM. In the cited study, the design of the experiment did
not allow for any conclusion on the mechanism of inhibition: inhibitor candidates were mixed
with HeLa nuclear extract before addition of HDAC fluorometric substrate which was
sensitized through deacetylation and fluorescence. Hence, only the consequence of the
presence of potential inhibitor was measured. In leukemia cell lines curcumin was shown to
increase expression of suppressors of cytokine signaling, SOCS1 and SOCS3, through global
inhibition of HDAC activity and decreased expression of HDAC8 [145]. In curcumin (25 μM,
24 h) treated Raji cells (Epstein-Barr virus transformed lymphocyte), a decrease of HDAC8 was
joined with similar levels of decrease of HDACs 1 and 3, leading to significant increase of
histone H4 acetylation [146]. Curcumin was also shown to reduce HDAC activity in medul‐
loblastoma cells and directly inhibits transcription of HDAC4 [147]. These results represent an
extension of previous scientific work showing that curcumin’s free binding energy and
inhibition constant for HDAC8 are comparable to trichostatin A and vorinostat [144].
Like luteolin, quercetin and resveratrol, curcumin (50 μM) inhibits histone demethylase
activity of recombinant LSD1 [76].
Curcumin can induce epigenetic modifications by modulating not only histone acetylation but
also DNA methylation. It is considered to be a hypomethylating agent decreasing DNMT
activity [137, 148]. Similarly to genistein and EGCG, curcumin (10 μM) has been demonstrated
to have the potential to reverse the epigenetic changes in breast cancer cells through inducing
significant decrease in protein levels of DNMT1, HDAC1 and MeCP2 as well as in the transcript
levels of all three DNMTs, DNMT1, DNMT3a and DNMT3b [117]. Curcumin has been found
to covalently block the catalytic thiol group within catalytic site of DNMT1 with an IC50 of only
3 μM after 72 h treatment, leading to reduction of DNA methylation by 15-20%, as shown in
the model of AML cell line MV4-11 [148]. Curcumin treatment decreased the mRNA and
protein levels of DNMT1 and downregulated its DNA methylation activity in breast cancer
cells MCF-7. The downregulation of DNMT1 mRNA may well be a consequence of lack of an
NF-κB/Sp1 binding to the promoter region of DNMT1 [149]. Both proteins are shown to bind
to DNMT1 promoter and positively regulate DNMT1 expression. Thus, in curcumin treated
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cells, a decrease of NF-κB and Sp1-well known curcumin targets, may directly influence the
activity of DNMT1 gene.
The most recent findings indeed confirm that curcumin decreases DNMT1 expression not only
in various leukemia cell lines, but also in patient’s primary AML cells treated ex vivo [150]. This
effect was concomitant with reactivation of tumor suppressor gene p15INK4B (p15) through
hypomethylation of its promoter, G1 cell cycle arrest, and in vitro induction of apoptosis. This
effect is, again, specific for transformed cells as it is absent in patient’s healthy PBMCs treated
in this way.
In contrast to non-specific global hypomethylation induced by decitabine, curcumin treatment
of three colorectal cancer cell lines HCT116, HT29 and RKO, resulted in methylation changes
at selected partially-methylated loci, instead of fully-methylated CpG site [151]. Curcumin has
also been found to selectively induce demethylation of promoters of NRF2 and RARβ2 genes
[152]. It also down-regulated expression of EZH2 and thus reduced H3K27me3 methylation,
as shown in in MDA-MB-435 cells [153].
Figure 3. Epigenetic modifications induced by selected polyphenols. Molecular mechanisms of action depends upon
their structures – flavonols and flavones directly inhibit histone demethylase LSD1 and indirectly DNMTs (Figure 2);
genistein promotes HAT activity and DNA demethylation; EGCG is a direct DNMT inhibitor; curcumin affects many epi‐
genome modifying enzymes.
Epigenetics and Epigenomics196
13. Conclusion
Experimental data reported so far clearly point to dietary polyphenols as potent epigenetic
modulators, able to "restore" disturbed epigenomic network which is present in premalignant
and malignant cells. Polyphenols usually target more than one epigenome-modulating
enzyme. In the case of curcumin the effect can be extended to enzymes with antagonistic
functions. This is very interesting as it opens the question related to “epigenetic balance” and
"epigenetically balanced cell". With our current knowledge, we cannot predict all possible
consequences of these polyvalent modes of action.
The epigenetic effects of polyphenols are largely dependent upon compound concentration,
its application time window, and, very important – on a specifically established epigenome
networking which is specific for each cancer cell. As xenobiotics, natural polyphenols are
substrates of various metabolic enzymes. Upon cellular uptake they can be chemically
transformed by various metabolic processes that depend on both, compound concentration
and the type of the cell. When studying biological effects of polyphenols, their chemical
characterization has to be performed in order to detect the most probably active form.
In  summary,  herein  considered  flavonoids  and  curcumin  represent  attractive  starting
scaffolds for design of chemopreventive or therapeutic drugs against various cancer types.
In addition, due to specific effects on epigenome, they may be useful as chemical probes
that may help to understand effects of natural and synthetic molecules on epigenome and
chromatin remodeling.
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